QUOTED. 14 August 2020. Jonathan Walker.
Updated guidance from England’s National Institute for Health and Care Excellence says two neurostimulation systems for treatment-resistant depression and epilepsy should only be used under special conditions. See what LivaNova’s VP of difficult-to-treat depression, Jonathan Walker, said about it here.
“We believe the updated guidance supports the growing body of evidence for VNS therapy, which includes published outcomes from a recent, large trial that demonstrated real-world evidence where VNS therapy, when added to conventional treatment, showed a significant improvement in response and remission.” – Jonathan Walker, VP of difficult-to-treat depression, LivaNova
- Find out more: NICE Updates Neurostim Guidance For Depression, Epilepsy
Click here for a free trial of Medtech Insight